fashion -WSS

fashion

author：explore 2025-09-09 05:34:11 - browse：29747

Immunofluorescence image shows CD4+ (green) and CD8+ (yellow) T cells in the microenvironment of a head and neck squamous cell carcinoma. — This immunofluorescence image shows T cells (in green and yellow) in the microenvironment of a head and neck squamous cell carcinoma. Allen Lab/NCI/NIH

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial.

The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.

But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Intarcia’s device

knowledge

WSS

Experts study whether long Covid risk adds up with each reinfection

Readout LOUD podcast: possible new ALS drug, artificial wombs

Why Titanic fascinates society, still drawing tours to the wreckage

Why are Kaiser Permanente staff considering a strike?

UPS workers' union leader explains what's at stake as strike edges closer

North Korean leader's powerful sister says warplanes repelled US spy plane

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The PBM ad wars are taking over Washington, D.C.

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Thermo Fisher plant for manufacturing gene therapies to expand

As demand for Covid shots wanes, Moderna seeks its next success

Intarcia’s device

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Senators: Long

Alkermes shareholders re

How Vertex's cystic fibrosis drug is changing patients' lives

hotspot

It's been 20 years since Dolly the sheep. Where's my clone?

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Why are Kaiser Permanente staff considering a strike?

Readout LOUD podcast: possible new ALS drug, artificial wombs

Drug for rare kidney disease narrowly misses mark in clinical trial

Readout LOUD podcast: possible new ALS drug, artificial wombs

hotspot

knowledge

entertainment

leisure time